Online Program Home
My Program

CC = Vancouver Convention Centre   F = Fairmont Waterfront Vancouver
* = applied session       ! = JSM meeting theme

Activity Details

247 ! Mon, 7/30/2018, 2:00 PM - 3:50 PM CC-West 205
Clinical Trial Design- 2 — Contributed Papers
Biopharmaceutical Section
Chair(s): Weining Robieson
2:05 PM Extension of Bayesian Logistic Regression Model (BLRM) for Dose Timing Selection in Oncology Phase I Combination Studies
Yiyun Zhang, Novartis; Nigel Yateman, Novartis; Fang Xiang, Novartis; Lan Yi, Novartis; Kapildeb Sen, Novartis; Beat Neuenschwander, Novartis
2:20 PM Considering Delayed Treatment Effect in Trial Designs with Survival Endpoints

Kaushal Mishra, Novartis Oncology Pharmaceuticals; Kalyanee Viraswami Appanna, Novartis Pharmaceuticals
2:35 PM Application of Bayesian Analyzes to Doubly-Randomized Delayed-Start, Matched Control Designs to Demonstrate Disease Modification

Ibrahim Turkoz, Janssen Research and Development, LLC; Marcus Sobel, Temple Universisity; Larry Alphs, Janssen Scientific Affairs, LLC
2:50 PM A Strategy for the Design and Analysis of Bridging Studies

Eric Holmgren, Beigene
3:05 PM Bayesian Isotonic Optimal Dose Design for Phase I/II Clinical Trials with Ordered Groups

Xiaoqiang Xue
3:20 PM Evaluation of Regional Efficacy Equivalence in Developing Biosimilars
Ryuji Uozumi, Kyoto University Graduate School of Medicine; Shinjo Yada, A2 Healthcare Corporation
3:35 PM Statistical Methodologies to Detect Ineffective Regional Treatment Effect in a Multiregional Trial
Hsiao-Hui Tsou, National Health Research Institutes; Yu-Chieh Cheng, National Health Research Institutes; Chin-Fu Hsiao, National Health Research Institutes